Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation
In this medfyle
Glucagon-like peptide-1 has broad actions across body systems.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About the Expert
Vanita R. Aroda, MD
Brigham and Women's Hospital, Boston, MA
Vanita Aroda, MD, is Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is Member of the Faculty at Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes, and Metabolism at the University of California, San Diego, CA, USA.
Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She has a strong interest in understanding therapeutic interventions in large multicenter clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership. Dr. Aroda serves on the American Diabetes Association's Professional Practice Committee.
Disclosures:
Within the preceding 12 months, Dr. Aroda has served as a consultant for Applied Therapeutics, Duke, Novo Nordisk, Pfizer, Sanofi. Her spouse is an employee of Janssen. Her institution has received research support through institutional contracts for her role in clinical trials from Applied Therapeutics/Medpace, Eli Lilly, Premier/Fractyl, Novo Nordisk, Sanofi/Medpace.
Acknowledgements
This summary is based upon an article appearing in the journal entitled Endocrine Reviews published by Oxford University Press and was created by GlobalPort. Oxford University Press takes no responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Vanita R. Aroda, MD.
Original article:
Brent A McLean, Chi Kin Wong, Jonathan E Campbell, David J Hodson, Stefan Trapp, Daniel J Drucker, Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation, Endocrine Reviews, Volume 42, Issue 2, April 2021, Pages 101–132, https://doi.org/10.1210/endrev/bnaa032
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of Endocrine Society/Oxford University Press.
This activity is supported by an educational grant from Lilly.
References
1. Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest 2017;127(12):4217–27.
2. Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95(2):513–48.
3. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019;30:72–130.
